TNF‐α antagonist may not be suitable for severe rituximab‐induced interstitial lung disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2710|40|3|249-250

ISSN： 0269-4727

Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.40, Iss.3, 2015-06, pp. : 249-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk Factors for Rituximab-Induced Interstitial Lung Diseases in Patients with Malignant Lymphoma

By  

Respiration, Vol. 85, Iss. 2, 2012-12 ,pp. : 175-175

Karger

Access to resources Recommend Favorite

Subclinical cardiovascular disease and it's improvement after long‐term TNF‐α inhibitor therapy in severe psoriatic patients

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 30, Iss. 9, 2016-09 ,pp. : 1531-1536

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab-Induced Hypersensitivity Pneumonitis

By  

Respiration, Vol. 78, Iss. 2, 2008-10 ,pp. : 225-229

Karger

Access to resources Recommend Favorite

Interstitial Lung Disease Induced by Drugs and Radiation

By  

Respiration, Vol. 71, Iss. 4, 2004-08 ,pp. : 301-326

Karger

Access to resources Recommend Favorite

Rituximab-Induced Interstitial Pneumonia due to CD8-Positive T Cell Infiltration

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 107-109

Karger

Access to resources Recommend Favorite